MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.2505
-0.0031
-1.22%
Pre Market: 0.2502 -0.0003 -0.12% 05:35 12/18 EST
OPEN
0.2499
PREV CLOSE
0.2536
HIGH
0.2660
LOW
0.2419
VOLUME
761.27K
TURNOVER
0
52 WEEK HIGH
1.730
52 WEEK LOW
0.2242
MARKET CAP
8.95M
P/E (TTM)
-0.4275
1D
5D
1M
3M
1Y
5Y
1D
Akari Therapeutics Announces $5M Financing Agreement
TipRanks · 21h ago
Akari Therapeutics Approves Key Resolutions at Meeting
TipRanks · 1d ago
Akari Therapeutics plc held a special general meeting of shareholders
Reuters · 1d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 1d ago
Akari Therapeutics announces $5M financing
TipRanks · 1d ago
Akari Therapeutics To Issue ~12.6M ADSs And Series G Warrants At $0.3883–$0.4041, Raising Gross Process Of ~$5M
Benzinga · 1d ago
AKARI THERAPEUTICS ANNOUNCES $5 MILLION FINANCING, INCLUDING CONCURRENT REGISTERED DIRECT OFFERING AND PRIVATE PLACEMENT PRICED AT-MARKET
Reuters · 1d ago
Weekly Report: what happened at AKTX last week (1208-1212)?
Weekly Report · 3d ago
More
About AKTX
Akari Therapeutics, Plc is a biotechnology company developing precision bifunctional antibody drug conjugates (ADC) for the treatment of cancer. Utilizing its ADC discovery platform, it generates bifunctional ADC candidates and optimizes them based on the desired application to target a range of cancers. Its lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells, and with a proprietary linker, delivers its novel PH1 payload directly into the tumor. PH1 is a novel bifunctional payload that is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while generating immunostimulatory effects and minimizing off-target toxicity. Its pipeline includes AKTX-101 and AKTX-102, a discovery-stage ADC that pairs PH1 with an undisclosed target antibody. It is pursuing research on two additional novel payloads, such as PH5 and PH6. It also has an ADC Platform for oncology and PHP-303 program for genetic disease, liver disease and inflammation.

Webull offers Akari Therapeutics PLC (ADR) stock information, including NASDAQ: AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.